Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study-Reference-Cited by-同舟云学术

Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study

Published:2016-07-28 Issue:4 Volume:128 Page:594-602
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Bochtler Tilmann¹²,Hegenbart Ute¹²,Kunz Christina³,Benner Axel³,Kimmich Christoph¹²,Seckinger Anja²,Hose Dirk²,Goldschmidt Hartmut²⁴,Granzow Martin⁵,Dreger Peter²,Ho Anthony D.¹²,Jauch Anna⁵,Schönland Stefan O.¹²

Affiliation:

1. Amyloidosis Center, and

2. Division of Hematology/Oncology/Rheumatology, Department of Internal Medicine, University of Heidelberg, Heidelberg, Germany;

3. Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany;

4. National Center for Tumor Diseases, Heidelberg, Germany; and

5. Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany

Abstract

Key Points Translocation t(11;14) confers a favorable prognosis in AL amyloidosis patients treated with HDM.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/128/4/594/1398306/594.pdf

Reference50 articles.

1. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.;Comenzo;Blood,1998

2. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.;Skinner;Ann Intern Med,2004

3. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study.;Dispenzieri;Blood,2004

4. Re-examining the role of high-dose chemotherapy in the treatment of light chain amyloidosis.;Devine;Biol Blood Marrow Transplant,2014

5. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.;Palladini;Blood,2004

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Light-chain Amyloidosis with Concomitant Symptomatic Myeloma (CRAB-SLiM Features): Clinical Characteristics, Cytogenetic Abnormalities, and Outcomes;2024-01-25

2. Treatment of Amyloid Light-Chain Amyloidosis;Cardiac Amyloidosis;2024

3. Hematopoietic Cell Transplantation in Light Chain Amyloidosis;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024

4. Daratumumab for the treatment of relapsed/refractory AL amyloidosis: experience from the amyloidosis Program of Calgary (APC);Leukemia & Lymphoma;2023-12-06

5. Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapies;Blood Cancer Journal;2023-11-15